Tau phosphorylation and aggregation as a therapeutic target in tauopathies

Nahuai Badiola, Marc Suárez-Calvet, Alberto Lleó

Producció científica: Contribució a revistaArticleRecercaAvaluat per experts

21 Cites (Scopus)

Resum

Tauopathies are neurodegenerative diseases characterized by insoluble hyperphosphorylated deposits of the microtubule associated protein tau in the central nervous system. In these disorders, tau is believed to cause neurodegeneration and neuronal loss due to the loss of function of the normal protein, and/or the gain of toxic properties by generating multimeric species. The obstacles found in amyloid-based therapies in Alzheimer's disease, the most common tauopathy, have stimulated the search for alternative targets, including tau. In this article, we review the strategies aimed at reducing tau phosphorylation and aggregation as a target for drug intervention in tauopathies. © 2010 Bentham Science Publishers.
Idioma originalAnglès
Pàgines (de-a)727-740
RevistaCNS and Neurological Disorders - Drug Targets
Volum9
Número6
DOIs
Estat de la publicacióPublicada - 1 de gen. 2010

Fingerprint

Navegar pels temes de recerca de 'Tau phosphorylation and aggregation as a therapeutic target in tauopathies'. Junts formen un fingerprint únic.

Com citar-ho